Insmed reported Q4 2025 earnings on February 19, 2026, with revenue of $263.84 million, up 152.6% year-over-year. BRINSUPRI generated $144.6 million in its first full quarter and the company is guiding to at least $1 billion in 2026 revenue. However, the company reported a loss per share of $1.54, missing the consensus estimate of $1.07. ARIKAYCE revenue grew 22% in Q3 2025 compared to the prior year. The company ended 2025 with approximately $1.4 billion in cash and projects cash-flow positivity without requiring additional capital. On the same day as earnings, Insmed Chair and CEO William Lewis sold over $1.6 million in company stock while exercising options to acquire shares. Analyst ratings remain mixed, with H.C. Wainwright maintaining a Buy rating and Mizuho maintaining an Outperform rating.
Read full analysisInsmed reported Q4 2025 earnings on February 19, 2026, with revenue of $263.84 million, up 152.6% year-over-year. BRINSUPRI generated $144.6 million in its first full quarter and the company is guiding to at least $1 billion in 2026 revenue. However, the company reported a loss per share of $1.54, missing the consensus estimate of $1.07. ARIKAYCE revenue grew 22% in Q3 2025 compared to the prior year. The company ended 2025 with approximately $1.4 billion in cash and projects cash-flow positivity without requiring additional capital. On the same day as earnings, Insmed Chair and CEO William Lewis sold over $1.6 million in company stock while exercising options to acquire shares. Analyst ratings remain mixed, with H.C. Wainwright maintaining a Buy rating and Mizuho maintaining an Outperform rating.
Insmed is a biopharmaceutical company focused on serious respiratory diseases. Its flagship product ARIKAYCE treats a rare lung infection, while its newly launched BRINSUPRI (brensocatib) targets non-cystic fibrosis bronchiectasis — a condition with no prior approved treatment. BRINSUPRI generated $144.6 million in its first full quarter, and management is guiding to at least $1 billion in 2026 revenue, positioning the drug as a potential blockbuster.